COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04323761




Registration number
NCT04323761
Ethics application status
Date submitted
24/03/2020
Date registered
27/03/2020
Date last updated
13/11/2020

Titles & IDs
Public title
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
Scientific title
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection
Secondary ID [1] 0 0
2020-001453-49
Secondary ID [2] 0 0
GS-US-540-5821
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
SARS-CoV2 Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections

Intervention/exposure
Study type
Expanded Access
Description of intervention(s) / exposure
Treatment: Drugs - Remdesivir

Treatment: Drugs: Remdesivir
Intravenous infusion administered over a 30 to 120 minute period

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
- Willing and able to provide written informed consent, or with a legal representative
who can provide informed consent, or enrolled under International Conference on
Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the
investigator (participants = 18 years of age), or willing and able to provide assent
(participants = 12 and < 18 years of age, where locally and nationally approved) prior
to performing study procedures. For participants = 12 and < 18 years of age, a parent
or legal guardian willing and able to provide written informed consent prior to
performing study procedures.

- Age = 18 years or aged = 12 and < 18 years of age weighing = 40 kg (where permitted
according to local law and approved nationally and by the relevant institutional
review board (IRB) or independent ethics committee (IEC))

- Hospitalized with confirmed SARS-CoV2 by polymerase chain reaction (PCR) or known
contact of confirmed case with syndrome consistent with coronavirus disease (COVID-19)
with PCR pending

- Oxygen saturation (SpO2) = 94% on room air or requiring supplemental oxygen at
baseline

- Alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) by local laboratory
measure and/or ALT < 3 x ULN and bilirubin < 2 x ULN

- Females of childbearing potential who engage in heterosexual intercourse must agree to
use protocol specified method(s) of contraception

- Lactating females must agree to discontinue nursing before the study drug is
administered and while they are participating in the study
Minimum age
12 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Evidence of multiorgan failure including but not limited to coagulopathy (significant
thrombocytopenia), hepatic failure (elevated bilirubin) or renal failure (low urine
output or estimated glomerular filtration rate (eGFR) < 30 mL/min), or significant
cardiomyopathy (low cardiac output)

- Use of more than 1 pressor for septic shock (note that use of 1 pressor at low/medium
doses for inotropic support due to the use of sedation and paralytics while on the
ventilator is allowed)

- Renal failure (eGRF < 30 mL/min using the Cockcroft-Gault formula for participants =
18 years of age and Schwartz Formula for participants < 18 years of age) or dialysis
or continuous Veno-Venous Hemofiltration)

- Eligible for enrollment in a randomized clinical trial studying remdesivir for
treatment of SARS-CoV2 at the medical facility where the participant is admitted

- Known hypersensitivity to the study drug, the metabolites, or formulation excipient

- Requiring venous arterial (V-A) extracorporeal membrane oxygen (ECMO) (venous venous
(V-V) ECMO is not an exclusion criteria)

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Approved for marketing
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
St. Vincent's Hospital Sydney - Darlinghurst
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [3] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment hospital [5] 0 0
Gold Coast Hospital - Southport
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment postcode(s) [5] 0 0
4215 - Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oklahoma
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
Rhode Island
Country [24] 0 0
United States of America
State/province [24] 0 0
South Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
United States of America
State/province [30] 0 0
Wisconsin
Country [31] 0 0
Austria
State/province [31] 0 0
Graz
Country [32] 0 0
Austria
State/province [32] 0 0
Innsbruck
Country [33] 0 0
Austria
State/province [33] 0 0
Linz
Country [34] 0 0
Austria
State/province [34] 0 0
Vienna
Country [35] 0 0
Austria
State/province [35] 0 0
Wien
Country [36] 0 0
Belgium
State/province [36] 0 0
Brussels
Country [37] 0 0
Belgium
State/province [37] 0 0
Ghent
Country [38] 0 0
Belgium
State/province [38] 0 0
Hasselt
Country [39] 0 0
Belgium
State/province [39] 0 0
Kortrijk
Country [40] 0 0
Belgium
State/province [40] 0 0
Leuven
Country [41] 0 0
Belgium
State/province [41] 0 0
Liège
Country [42] 0 0
Belgium
State/province [42] 0 0
Lodelinsart
Country [43] 0 0
Canada
State/province [43] 0 0
Ontario
Country [44] 0 0
Cyprus
State/province [44] 0 0
Nicosia
Country [45] 0 0
Czechia
State/province [45] 0 0
Prague
Country [46] 0 0
Czechia
State/province [46] 0 0
Praha 5
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 8 - Liben
Country [48] 0 0
Denmark
State/province [48] 0 0
Copenhagen
Country [49] 0 0
Estonia
State/province [49] 0 0
Tallinn
Country [50] 0 0
Estonia
State/province [50] 0 0
Tartu
Country [51] 0 0
France
State/province [51] 0 0
Bobigny
Country [52] 0 0
France
State/province [52] 0 0
Brest Cedex
Country [53] 0 0
France
State/province [53] 0 0
Clermont Ferrand
Country [54] 0 0
France
State/province [54] 0 0
Colmar
Country [55] 0 0
France
State/province [55] 0 0
Corbeil Essonnes
Country [56] 0 0
France
State/province [56] 0 0
Garches
Country [57] 0 0
France
State/province [57] 0 0
Orléans
Country [58] 0 0
France
State/province [58] 0 0
Poitiers
Country [59] 0 0
France
State/province [59] 0 0
Rouen
Country [60] 0 0
France
State/province [60] 0 0
Toulouse
Country [61] 0 0
Germany
State/province [61] 0 0
Bochum
Country [62] 0 0
Germany
State/province [62] 0 0
Dresden
Country [63] 0 0
Germany
State/province [63] 0 0
Essen
Country [64] 0 0
Germany
State/province [64] 0 0
Freiburg
Country [65] 0 0
Germany
State/province [65] 0 0
Göttingen
Country [66] 0 0
Germany
State/province [66] 0 0
Hannover
Country [67] 0 0
Germany
State/province [67] 0 0
Heidelberg
Country [68] 0 0
Germany
State/province [68] 0 0
Homburg
Country [69] 0 0
Germany
State/province [69] 0 0
Regensburg
Country [70] 0 0
Germany
State/province [70] 0 0
Würzburg
Country [71] 0 0
Greece
State/province [71] 0 0
Patra
Country [72] 0 0
Greece
State/province [72] 0 0
Thessaloniki
Country [73] 0 0
Hungary
State/province [73] 0 0
Debrecen
Country [74] 0 0
Iceland
State/province [74] 0 0
Reykjavik
Country [75] 0 0
Ireland
State/province [75] 0 0
Tralee
Country [76] 0 0
Israel
State/province [76] 0 0
Jerusalem
Country [77] 0 0
Israel
State/province [77] 0 0
Petah Tikva
Country [78] 0 0
Israel
State/province [78] 0 0
Ramat Gan
Country [79] 0 0
Italy
State/province [79] 0 0
Ancona
Country [80] 0 0
Italy
State/province [80] 0 0
Bari
Country [81] 0 0
Italy
State/province [81] 0 0
Bologna
Country [82] 0 0
Italy
State/province [82] 0 0
Brescia
Country [83] 0 0
Italy
State/province [83] 0 0
Catania
Country [84] 0 0
Italy
State/province [84] 0 0
Florence
Country [85] 0 0
Italy
State/province [85] 0 0
Genova
Country [86] 0 0
Italy
State/province [86] 0 0
Milano
Country [87] 0 0
Italy
State/province [87] 0 0
Monza
Country [88] 0 0
Italy
State/province [88] 0 0
Napoli
Country [89] 0 0
Italy
State/province [89] 0 0
Pisa
Country [90] 0 0
Italy
State/province [90] 0 0
Roma
Country [91] 0 0
Italy
State/province [91] 0 0
Turin
Country [92] 0 0
Lithuania
State/province [92] 0 0
Kaunas
Country [93] 0 0
Lithuania
State/province [93] 0 0
Vilnius
Country [94] 0 0
Netherlands
State/province [94] 0 0
Nijmegen
Country [95] 0 0
Netherlands
State/province [95] 0 0
The Hague
Country [96] 0 0
Poland
State/province [96] 0 0
Krakow
Country [97] 0 0
Poland
State/province [97] 0 0
Lodz
Country [98] 0 0
Poland
State/province [98] 0 0
Poznan
Country [99] 0 0
Poland
State/province [99] 0 0
Tychy
Country [100] 0 0
Portugal
State/province [100] 0 0
Lisboa
Country [101] 0 0
Portugal
State/province [101] 0 0
Porto
Country [102] 0 0
Portugal
State/province [102] 0 0
Vila Nova de Gaia
Country [103] 0 0
Romania
State/province [103] 0 0
Bucharest
Country [104] 0 0
Romania
State/province [104] 0 0
Iasi
Country [105] 0 0
Romania
State/province [105] 0 0
Timisoara
Country [106] 0 0
Slovakia
State/province [106] 0 0
KoŇ°ice
Country [107] 0 0
Slovenia
State/province [107] 0 0
Ljubljana
Country [108] 0 0
Slovenia
State/province [108] 0 0
Maribor
Country [109] 0 0
Spain
State/province [109] 0 0
Badalona
Country [110] 0 0
Spain
State/province [110] 0 0
Madrid
Country [111] 0 0
Spain
State/province [111] 0 0
Oviedo
Country [112] 0 0
Spain
State/province [112] 0 0
Palma de Mallorca
Country [113] 0 0
Spain
State/province [113] 0 0
Salamanca
Country [114] 0 0
Spain
State/province [114] 0 0
San Sebastian
Country [115] 0 0
Spain
State/province [115] 0 0
Santa Cruz de Tenerife
Country [116] 0 0
Spain
State/province [116] 0 0
Toledo
Country [117] 0 0
Spain
State/province [117] 0 0
Valladolid
Country [118] 0 0
Spain
State/province [118] 0 0
Zaragoza
Country [119] 0 0
Switzerland
State/province [119] 0 0
Aarau
Country [120] 0 0
Switzerland
State/province [120] 0 0
Basel
Country [121] 0 0
Switzerland
State/province [121] 0 0
Biel
Country [122] 0 0
Switzerland
State/province [122] 0 0
Chur
Country [123] 0 0
Switzerland
State/province [123] 0 0
Lausanne
Country [124] 0 0
Switzerland
State/province [124] 0 0
Luzern
Country [125] 0 0
Switzerland
State/province [125] 0 0
Sion
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Cardiff
Country [127] 0 0
United Kingdom
State/province [127] 0 0
London
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the
treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
Trial website
https://clinicaltrials.gov/show/NCT04323761
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gilead Study Director
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04323761